US Stock Market Move | Palantir (PLTR.US) fell more than 6.7% in response to its impressive Q3 financial report, but the market is concerned that its valuation is too high.
As of press time, the stock has fallen more than 6.7%, reporting $193.2 per share.
On Tuesday, Palantir (PLTR.US) stock price dropped, falling more than 6.7% to $193.2 per share as of the time of writing. On the news front, Palantir reported third-quarter revenue of $11.8 billion, a 63% increase year-over-year, surpassing analysts' expectations of $10.9 billion. The company expects fourth-quarter revenue to be $13.3 billion, higher than analysts' expectations of $11.9 billion.
Deutsche Bank Aktiengesellschaft strategist Jim Reid wrote in a report, "Their performance is good, but the market is disappointed by the lack of clarity on the company's performance outlook for the whole of 2026." He also mentioned concerns in the market about Palantir being overvalued. As of Monday's close, Palantir's stock price has risen by 173% year-to-date, with a forward price-earnings ratio exceeding 200 times.
Related Articles

Infotmic Co., Ltd. shareholder Orient intends to reduce its shareholding by no more than 3%.

US Stock Market Move | Royal Philips N.V. Sponsored ADR (PHG.US) rises 3% in Q3, adjusted EBITA exceeds expectations.

US Stock Market Move | Hot Chinese concept stocks generally fell, with Futu Holdings Ltd. Sponsored ADR Class A (FUTU.US) falling more than 5%.
Infotmic Co., Ltd. shareholder Orient intends to reduce its shareholding by no more than 3%.

US Stock Market Move | Royal Philips N.V. Sponsored ADR (PHG.US) rises 3% in Q3, adjusted EBITA exceeds expectations.

US Stock Market Move | Hot Chinese concept stocks generally fell, with Futu Holdings Ltd. Sponsored ADR Class A (FUTU.US) falling more than 5%.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


